Momentum Engineering & Surveying
Momentum Therapeutics develops neuroprotective drugs targeting the biological mechanisms of aging to treat neurodegenerative diseases. Their preclinical-stage therapies aim to address unmet needs in conditions like Alzheimer's and Parkinson's.
- Biotechnology
Funding
Funding not disclosed
Founders
Founder details are not available yet.
Product
Problem
Neurodegenerative diseases like Alzheimer's and Parkinson's pose a significant global medical challenge, with aging being the most prominent risk factor. Current therapeutic approaches often target individual diseases, neglecting the underlying aging mechanisms that contribute to neuronal dysfunction and degeneration. This leaves a substantial unmet need for therapies that address the root causes of age-related neurological decline.
Solution
Momentum Therapeutics is developing a pipeline of neuroprotective drugs that target the biological mechanisms of aging to treat neurodegenerative diseases. Their approach focuses on restoring the protein landscape in the central and peripheral nervous systems, which is altered during aging and contributes to tissue dysfunction and connectivity loss. By combining in silico, in vitro, and in vivo methods, Momentum Therapeutics identifies existing and novel drug targets that can reverse these age-related protein modifications. Their preclinical-stage therapies aim to protect and repair the nervous system by addressing the fundamental aging processes that drive neurodegeneration.
Target Audience
The primary target audience includes individuals at risk of or affected by neurodegenerative diseases, as well as pharmaceutical companies and research institutions focused on developing therapies for age-related neurological conditions.
Features
- Utilizes proteomics data, including 7,000 protein levels and access to a 1,300 protein library, to identify protein modules that change in the aged brain.
- Maps the direction and magnitude of protein changes to generate a protein landscape of the aging brain.
- Employs in silico, in vitro, and in vivo models to test candidate molecules in clinically relevant biomedical models of aging and neurodegeneration.
- Focuses on identifying and validating drug targets associated with human aging to address age-related brain diseases.